Five-year SENOMAC trial results show omitting completion axillary dissection preserves survival and significantly reduces arm morbidity, says Jana de Boniface, MD, PhD.
Jana de Boniface, MD
Advertisement
Jana de Boniface, MD, is a general surgeon specializing in oncoplastic breast surgery at Karolinska Institutet.
Articles by Jana de Boniface, MD
SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting quality of life.
Advertisement
Latest Updated Articles
Dr de Boniface on Encouraging SENOMAC Trial DataMay 30th 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
4
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
5